Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LB PHARMACEUTICALS INCLBRX · Entity 4678 | Director | September 10, 2025 | September 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LB PHARMACEUTICALS INC
Report date September 10, 2025 · Filed September 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.15 · Expires 2028-11-13 | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-10 · Disposition to issuer · Disposed 3,944 · Balance 0 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: Immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2028-11-13 | Direct | 3,944 |
Reported balance
After 2025-09-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-09-10 · Grant · Acquired 3,944 · Balance 3,944 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: Immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.72 · Expires 2029-12-22 | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-09-10 · Disposition to issuer · Disposed 896 · Balance 0 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: Immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-12-22 | Direct | 896 |
Reported balance
After 2025-09-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-09-10 · Grant · Acquired 896 · Balance 896 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: Immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.72 · Expires 2030-08-30 | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-09-10 · Disposition to issuer · Disposed 1,255 · Balance 0 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: Immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2030-08-30 | Direct | 1,255 |
Reported balance
After 2025-09-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-09-10 · Grant · Acquired 1,255 · Balance 1,255 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: Immediately exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.84 · Expires 2033-08-24 | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-09-10 · Disposition to issuer · Disposed 17,929 · Balance 0 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F3: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2033-08-24 | Direct | 17,929 |
Reported balance
After 2025-09-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-09-10 · Grant · Acquired 17,929 · Balance 17,929 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F3: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.84 · Expires 2034-06-26 | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-09-10 · Disposition to issuer · Disposed 53,787 · Balance 0 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F4: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2034-06-26 | Direct | 53,787 |
Reported balance
After 2025-09-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-09-10 · Grant · Acquired 53,787 · Balance 53,787 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F4: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2035-09-09 | Direct | 22,449 |
Reported balance
After 2025-09-10 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-09-10 · Grant · Acquired 22,449 · Balance 22,449 F5: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately exercisable.
F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.
F3: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F4: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F5: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 22,449 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 11 PRENSKY ZACHARY · CIK 0001167585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,449 Underlying: Common Stock · 22,449 shares Expires 2035-09-09 F5 · derivative.exercise_date: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 53,787 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 10 PRENSKY ZACHARY · CIK 0001167585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,787 Underlying: Common Stock · 53,787 shares Expires 2034-06-26 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F4 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerStock Option (Right to Buy) · Derivative | 53,787 | Not disclosed Strike: $41.84 | Not disclosed |
DisclosureSEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 9 PRENSKY ZACHARY · CIK 0001167585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,787 shares Expires 2034-06-26 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F4 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 17,929 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 8 PRENSKY ZACHARY · CIK 0001167585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,929 Underlying: Common Stock · 17,929 shares Expires 2033-08-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,929 | Not disclosed Strike: $41.84 | Not disclosed |
DisclosureSEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 7 PRENSKY ZACHARY · CIK 0001167585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,929 shares Expires 2033-08-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 1,255 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 6 PRENSKY ZACHARY · CIK 0001167585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,255 Underlying: Common Stock · 1,255 shares Expires 2030-08-30 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,255 | Not disclosed Strike: $69.72 | Not disclosed |
DisclosureSEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 5 PRENSKY ZACHARY · CIK 0001167585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,255 shares Expires 2030-08-30 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 896 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 4 PRENSKY ZACHARY · CIK 0001167585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 896 Underlying: Common Stock · 896 shares Expires 2029-12-22 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerStock Option (Right to Buy) · Derivative | 896 | Not disclosed Strike: $69.72 | Not disclosed |
DisclosureSEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 3 PRENSKY ZACHARY · CIK 0001167585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 896 shares Expires 2029-12-22 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantStock Option (Right to Buy) · Derivative | 3,944 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 2 PRENSKY ZACHARY · CIK 0001167585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,944 Underlying: Common Stock · 3,944 shares Expires 2028-11-13 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 22:25 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,944 | Not disclosed Strike: $64.15 | Not disclosed |
DisclosureSEC source: 0001415889-25-024448 · form4-09122025_060911.xml · derivative · entry 1 PRENSKY ZACHARY · CIK 0001167585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,944 shares Expires 2028-11-13 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.